Targeted therapies in control of EMT in carcinoma and fibrosis

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 4, 2007, Pages 261-267

  Chua, Kian Ngiap ^a,b   Ma, Jing ^a   Thiery, Jean Paul ^a,b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b Agency for Science   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; AP 12009; ATRASENTAN; BEVACIZUMAB; CETUXIMAB; CILENGITIDE; CYSTATIN C; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LERDELIMUMAB; METELIMUMAB; MONOCLONAL ANTIBODY LM 609; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PANITUMUMAB; PROTEIN TYROSINE KINASE; SCIO 469; SD 208; SORAFENIB; SUNITINIB; SV 203580; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER THERAPY; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HUMAN; INFLAMMATORY DISEASE; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; METASTASIS INHIBITION; NONHUMAN; OVARY CANCER; PANCREAS CANCER; RECEPTOR BLOCKING; REVIEW; SCAR FORMATION; SCLERODERMA; SIGNAL TRANSDUCTION; THYROID CANCER;

EID: 47049108537     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.06.002     Document Type: Review

References (54)

1. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15 (2003) 740-746
2. Thiery J.P., and Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7 (2006) 131-142
3. Moustakas A., and Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 98 (2007) 1512-1520
4. Braun S., et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18 (2000) 80-86
5. Pierga J.Y., et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 10 (2004) 1392-1400
6. Braun S., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353 (2005) 793-802
7. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
8. Arora A., and Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315 (2005) 971-979
9. Hatake K., et al. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways. Breast Cancer 14 (2007) 132-149
10. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2 (2002) 442-454
11. Cozzolino M., et al. p120 Catenin is required for growth factor-dependent cell motility and scattering in epithelial cells. Mol. Biol. Cell 14 (2003) 1964-1977
12. Dandachi N., et al. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J. Pathol. 193 (2001) 181-189
13. Lee J.M., et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172 (2006) 973-981
14. Maione P., et al. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 11 (2006) 274-284
15. McNeil C. Two targets, one drug for new EGFR inhibitors. J. Natl. Cancer Inst. 98 (2006) 1102-1103
16. Press M.F., and Lenz H.J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67 (2007) 2045-2075
17. Warmuth M., et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101 (2003) 664-672
18. Talpaz M., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 (2006) 2531-2541
19. Gridelli C., et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 12 (2007) 191-200
20. Park Y.W., et al. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin. Cancer Res. 11 (2005) 1963-1973
21. Zavadil J., et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6686-6691
22. Yingling J.M., et al. Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3 (2004) 1011-1022
23. Galliher A.J., et al. Role of transforming growth factor-beta in cancer progression. Future Oncol. 2 (2006) 743-763
24. Schiemann W.P. Targeted TGF-beta chemotherapies: friend or foe in treating human malignancies?. Expert Rev. Anticancer Ther. 7 (2007) 609-611
25. Moustakas A., and Heldin C.H. Non-Smad TGF-beta signals. J. Cell Sci. 118 (2005) 3573-3584
26. Sokol J.P., et al. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res. 7 (2005) R844-R853
27. Swallow C.J., et al. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res. 64 (2004) 6402-6409
28. Zhao B.M., and Hoffmann F.M. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol. Biol. Cell 17 (2006) 3819-3831
29. Eger A., et al. beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 23 (2004) 2672-2680
30. Ge R., et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin. Cancer Res. 12 (2006) 4315-4330
31. Bakin A.V., et al. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 115 (2002) 3193-3206
32. Hideshima T., et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23 (2004) 8766-8776
33. Waerner T., et al. ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell 10 (2006) 227-239
34. Wu C., and Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J. Cell Biol. 155 (2001) 505-510
35. Rosano L., et al. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol. Cancer Ther. 6 (2007) 2003-2011
36. Rosano L., et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 65 (2005) 11649-11657
37. Rosano L., et al. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol. Cancer Ther. 5 (2006) 833-842
38. Troussard A.A., et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66 (2006) 393-403
39. Younes M.N., et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol. Cancer Ther. 4 (2005) 1146-1156
40. Bhowmick N.A., et al. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J. Biol. Chem. 276 (2001) 46707-46713
41. Galliher A.J., and Schiemann W.P. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 8 (2006) R42
42. Bates R.C., et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 115 (2005) 339-347
43. Thomas G.J., et al. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J. Oral Pathol. Med. 35 (2006) 1-10
44. Burke P.A., et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 62 (2002) 4263-4272
45. Abdollahi A., et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin. Cancer Res. 11 (2005) 6270-6279
46. Stupp R., and Ruegg C. Integrin inhibitors reaching the clinic. J. Clin. Oncol. 25 (2007) 1637-1638
47. Brabletz T., et al. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5 (2005) 744-749
48. Mani S.A., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008) 704-715
49. Thomson S., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65 (2005) 9455-9462
50. Yang A.D., et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 12 (2006) 4147-4153
51. Frederick B.A., et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol. Cancer Ther. 6 (2007) 1683-1691
52. Rodier J.M., et al. pp60c-src is a positive regulator of growth factor-induced cell scattering in a rat bladder carcinoma cell line. J. Cell Biol. 131 (1995) 761-773
53. Yarrow J.C., et al. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem. Biol. 12 (2005) 385-395
54. Geiger T., et al. Anomalous features of EMT during keratinocyte transformation. PLoS ONE 3 (2008) e1574